01.12.2011Nintedanib (BIBF 1120*), a Boehringer Ingelheim investigational compound, is an oral triple angiokinase inhibitor which simultaneously blocks three angiogenesis signalling pathways and therefore affects tumour growth.
How does angiogenesis work?1
Angiogenesis is a normal function in the body that helps new blood vessels grow. It is necessary for wound healing, reproduction and embryo development. Angiogenesis is mediated through growth factors (VEGF, FGF and PDGF).
When blocking only one angiokinase...
...tumours can become resistant to VEGFR inhibition and use alternative signalling pathways, such as FGFR, to sustain growth.
How does nintedanib* work?2
Clinical trials showed that nintedanib* acts on all three receptors - FGFR, VEGFR and PDGFR, thereby inhibiting all signalling pathways involved in angiogenesis. This tumour stabilisation or shrinkage due to lack of oxygen and nutrients
*Nintedanib (BIBF 1120) is an investigational compound. Its safety and efficacy has not yet been fully established.